Ipca Labs. (IPCALAB)
Slow GrowerFairStock Score: 59/100 — STEADY
Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹1,734.2 |
| Market Cap | ₹43,997.38 Cr |
| P/E Ratio | 33.56 |
| ROCE | 14.72% |
| ROE | 13.22% |
| Dividend Yield | 0.34% |
| Profit Growth | 42.46% |
| Debt/Equity | 0.08 |
| Sales Growth | 20.58% |
| Free Cash Flow | ₹451 Cr |
| Promoter Holding | 44.72% |
| 52-Week Range | ₹1,268 — ₹2,039.3 |
| Sector | Pharmaceuticals & Biotechnology |
| Book Value | ₹317.84 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
Looking at Ipca Labs through my Graham-Buffett lens, I see a financially healthy pharma business with respectable, not spectacular, returns. Latest quarter sales were ₹2,393 Cr and net profit ₹364 Cr, while sales grew 20.58% and profit grew 42.46%. The five-year revenue CAGR of 14.01% suggests durable growth, not a one-quarter wonder. Debt/equity of 0.08, Altman Z-score 3.91, Piotroski F-score 8/9, and free cash flow of ₹451 Cr give me balance-sheet comfort. Promoter holding at 44.72% aligns interests. ROE of 13.22% and ROCE of 14.72% are acceptable but below the 20% I prefer. The moat may be modest: steady 14.01% revenue CAGR and an 8/9 F-score imply some durability, but the numbers don’t prove pricing power.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer